• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新加坡非特发性肺纤维化间质性肺疾病队列中的聚类表型

Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore.

作者信息

Kam Michelle Li Wei, Tiew Pei Yee, Chai Hui Zhong, Low Su Ying

机构信息

Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore.

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

出版信息

J Thorac Dis. 2022 Jul;14(7):2481-2492. doi: 10.21037/jtd-22-40.

DOI:10.21037/jtd-22-40
PMID:35928611
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9344411/
Abstract

BACKGROUND

Non-idiopathic pulmonary fibrosis fibrosing interstitial lung diseases (F-ILDs) may demonstrate a progressive disease trajectory similar to idiopathic pulmonary fibrosis (IPF). We aimed to identify novel F-ILD phenotypes in a multi-ethnic South-East Asian population.

METHODS

F-ILD subjects (n=201) were analysed using unsupervised hierarchical cluster analysis and their outcomes compared against IPF (n=86).

RESULTS

Four clusters were identified. Cluster 1 (n=53, 26.4%) comprised older Chinese males with high body mass index (BMI) and comorbidity burden, higher baseline forced vital capacity (FVC) percentage predicted and lower diffusing capacity of the lung for carbon monoxide (DLCO) percentage predicted. They had similar mortality to IPF. Cluster 2 (n=67, 33.3%) had younger female non-smokers with low comorbidity burden, groundglass changes on high-resolution chest computed tomography (HRCT) and a positive anti-nuclear antibody (ANA) titre ≥1:160. They had lower baseline FVC and higher DLCO, low mortality and slower lung function decline. Cluster 3 (n=42, 20.9%) consisted male smokers with low comorbidity burden, emphysema on HRCT and high baseline lung function. They had low mortality and slow lung function decline. Cluster 4 (n=39, 19.4%) was the highest risk and comprised of mainly Indians with high BMI. They had the highest proportion of ischemic heart disease (IHD) and previous pulmonary tuberculosis. Subjects had the lowest baseline lung function, highest mortality, and fastest lung function decline. Survival differences across clusters remained significant following adjustment for treatment.

CONCLUSIONS

We identified four distinct F-ILD clinical phenotypes with varying disease trajectories. This demonstrates heterogeneity in F-ILD and the need for complementary approaches for classification and prognostication beyond ATS/ERS guideline diagnosis.

摘要

背景

非特发性肺纤维化的纤维化间质性肺疾病(F-ILDs)可能呈现出与特发性肺纤维化(IPF)相似的疾病进展轨迹。我们旨在识别东南亚多民族人群中的新型F-ILD表型。

方法

对F-ILD受试者(n = 201)进行无监督分层聚类分析,并将其结果与IPF受试者(n = 86)进行比较。

结果

识别出四个聚类。聚类1(n = 53,26.4%)包括年龄较大、体重指数(BMI)较高且合并症负担较重的中国男性,基线用力肺活量(FVC)预测百分比较高,而肺一氧化碳弥散量(DLCO)预测百分比较低。他们的死亡率与IPF相似。聚类2(n = 67,33.3%)为年轻的非吸烟女性,合并症负担较轻,高分辨率胸部计算机断层扫描(HRCT)显示磨玻璃样改变,抗核抗体(ANA)滴度≥1:160阳性。他们的基线FVC较低,DLCO较高,死亡率较低,肺功能下降较慢。聚类3(n = 42,20.9%)由合并症负担较轻的男性吸烟者组成,HRCT显示有肺气肿,基线肺功能较高。他们的死亡率较低,肺功能下降较慢。聚类4(n = 39,19.4%)风险最高,主要由BMI较高的印度人组成。他们缺血性心脏病(IHD)和既往肺结核的比例最高。受试者的基线肺功能最低,死亡率最高,肺功能下降最快。调整治疗后,各聚类间的生存差异仍然显著。

结论

我们识别出四种具有不同疾病轨迹的F-ILD临床表型。这表明F-ILD存在异质性,除了美国胸科学会/欧洲呼吸学会指南诊断外,还需要补充方法进行分类和预后评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/d0b803205d39/jtd-14-07-2481-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/d6046e20fd16/jtd-14-07-2481-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/a41a0d9da6e7/jtd-14-07-2481-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/ed8d53afd8a0/jtd-14-07-2481-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/d0b803205d39/jtd-14-07-2481-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/d6046e20fd16/jtd-14-07-2481-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/a41a0d9da6e7/jtd-14-07-2481-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/ed8d53afd8a0/jtd-14-07-2481-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d61d/9344411/d0b803205d39/jtd-14-07-2481-f4.jpg

相似文献

1
Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore.新加坡非特发性肺纤维化间质性肺疾病队列中的聚类表型
J Thorac Dis. 2022 Jul;14(7):2481-2492. doi: 10.21037/jtd-22-40.
2
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.尼达尼布治疗进行性肺纤维化间质性肺疾病患者- INBUILD 试验中按间质性肺疾病诊断的亚组分析:一项随机、双盲、安慰剂对照、平行组试验。
Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.
3
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.结缔组织病相关性间质性肺炎与慢性纤维化特发性间质性肺炎的临床过程和死亡率比较。
Kaohsiung J Med Sci. 2019 Jun;35(6):365-372. doi: 10.1002/kjm2.12066. Epub 2019 Mar 26.
4
Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.表型聚类预测纵向间质性肺病队列的结局。
Chest. 2018 Feb;153(2):349-360. doi: 10.1016/j.chest.2017.09.026. Epub 2017 Sep 28.
5
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验:吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
6
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.进展性肺纤维化间质性肺疾病患者的死亡率预测因素。
Respirology. 2022 Apr;27(4):294-300. doi: 10.1111/resp.14231. Epub 2022 Feb 27.
7
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.吡非尼酮治疗无法分类的进行性纤维化间质性肺疾病患者:一项双盲、随机、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.
8
CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.血清、BAL 液和肺泡巨噬细胞培养上清液中的 CCL18 在间质性肺疾病中的作用。
Respir Med. 2013 Sep;107(9):1444-52. doi: 10.1016/j.rmed.2013.06.004. Epub 2013 Jul 5.
9
Tobacco smoking is associated with combined pulmonary fibrosis and emphysema and worse outcomes in interstitial lung disease.吸烟与肺纤维化合并肺气肿有关,并导致间质性肺疾病的预后更差。
Am J Physiol Lung Cell Mol Physiol. 2023 Aug 1;325(2):L233-L243. doi: 10.1152/ajplung.00083.2023. Epub 2023 Jun 27.
10
Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort.特发性肺纤维化患者的用力肺活量轨迹:一项多中心、前瞻性、观察性队列的二次分析。
Lancet Digit Health. 2022 Dec;4(12):e862-e872. doi: 10.1016/S2589-7500(22)00173-X. Epub 2022 Nov 1.

本文引用的文献

1
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.进展性纤维性间质性肺病:患病率和临床转归。
Respir Res. 2021 Oct 31;22(1):282. doi: 10.1186/s12931-021-01879-6.
2
Defining and predicting progression in non-IPF interstitial lung disease.定义和预测非特发性肺纤维化间质性肺病的进展。
Respir Med. 2021 Nov-Dec;189:106626. doi: 10.1016/j.rmed.2021.106626. Epub 2021 Oct 1.
3
Clusters of comorbidities in idiopathic pulmonary fibrosis.特发性肺纤维化中的合并症群。
Respir Med. 2021 Aug-Sep;185:106490. doi: 10.1016/j.rmed.2021.106490. Epub 2021 Jun 1.
4
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.吡非尼酮治疗非特发性肺纤维化的进展性肺纤维化间质性肺疾病患者(RELIEF):一项双盲、随机、安慰剂对照、2b 期试验。
Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.
5
Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.抗合成酶综合征相关间质性肺病的临床特征:中国的一项回顾性队列研究。
BMC Pulm Med. 2021 Feb 12;21(1):57. doi: 10.1186/s12890-021-01399-5.
6
A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.基于聚类的分析评估纤维化间质性肺疾病合并症的影响。
Respir Res. 2020 Dec 7;21(1):322. doi: 10.1186/s12931-020-01579-7.
7
Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease.包含查尔森合并症指数评分的综合评分系统在间质性肺疾病患者中的临床应用价值。
J Thorac Dis. 2020 Oct;12(10):5774-5782. doi: 10.21037/jtd-20-1302.
8
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).进行性纤维化间质性肺疾病:一项临床队列研究(PROGRESS研究)
Eur Respir J. 2021 Feb 11;57(2). doi: 10.1183/13993003.02718-2020. Print 2021 Feb.
9
The natural history of progressive fibrosing interstitial lung diseases.特发性肺纤维化等进行性纤维性间质性肺疾病的自然史。
Eur Respir J. 2020 Jun 25;55(6). doi: 10.1183/13993003.00085-2020. Print 2020 Jun.
10
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.吡非尼酮治疗无法分类的进行性纤维化间质性肺疾病患者:一项双盲、随机、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.